Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
暂无分享,去创建一个
Hans T. Chung | Liying Zhang | P. Cheung | M. McGuffin | E. Szumacher | L. D'alimonte | G. Morton | A. Loblaw | A. Ravi | Stanley K. Liu | A. Mamedov | J. Helou | Motasem Al-Hanaqta | H. Chung | L. D’Alimonte